Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology

Fineline Cube Nov 13, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration...

Company Deals

Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent

Fineline Cube Nov 13, 2023

On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...

Company Drug

Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark

Fineline Cube Nov 13, 2023

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...

Company

Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons

Fineline Cube Nov 13, 2023

It has been reported that Benjamin L. Basil, the current president and general manager of...

Company Drug

Clinical Research on rAAV Gene Drug ZS805 for Fabry Disease Launched by Zhishan Weixin

Fineline Cube Nov 13, 2023

Zhishan Weixin Biotechnology Co., Ltd, a China-based biotech company, has announced the launch of the...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Subsidiary Shengdi Pharmaceuticals Receives NMPA Approval for HRS-9057

Fineline Cube Nov 13, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that its...

Company Drug

Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA

Fineline Cube Nov 13, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company

Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters

Fineline Cube Nov 13, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the...

Company

Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe

Fineline Cube Nov 13, 2023

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites...

Company

Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments

Fineline Cube Nov 10, 2023

Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...

Company Deals

AimingMed Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine

Fineline Cube Nov 10, 2023

AimingMed, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a...

Company Drug

China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel

Fineline Cube Nov 10, 2023

The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...

Policy / Regulatory

China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Fineline Cube Nov 10, 2023

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults

Fineline Cube Nov 10, 2023

Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...

Company

BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase

Fineline Cube Nov 10, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...

Company Deals Hospital

Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties

Fineline Cube Nov 10, 2023

US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003

Fineline Cube Nov 10, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases

Fineline Cube Nov 10, 2023

Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...

Company Drug

Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China

Fineline Cube Nov 10, 2023

China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...

Company Deals

Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing

Fineline Cube Nov 10, 2023

China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon...

Posts pagination

1 … 437 438 439 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.